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Novel Avilamycin Derivatives with Improved
Polarity Generated by Targeted Gene Disruption
D), 4-O-methyl-D-fucose (residue E), 2,6-di-O-methyl-
D-mannose (residue F), L-lyxose (residue G), and eure-
kanate (residue H). Avilamycin A and avilamycin C are
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and Andreas Bechthold1,* the main products of S. viridochromogenes Tu¨57. The
structures of these compounds differ in one residue at1Pharmazeutische Biologie und Biotechnologie
Institut fu¨r Pharmazeutische Wissenschaften C56 of the molecule (avilamycin A: COCH3; avilamycin
C: CH(OH)CH3). Avilamycin and evernimicin, the mostAlbert-Ludwigs-Universita¨t Freiburg
Stefan-Meier-Strasse 19 prominent examples of the orthosomycins, show excel-
lent activity against a broad range of Gram-positive79104 Freiburg
Germany pathogenic bacteria including glycopeptide-resistant
enterococci, methicillin-resistant staphylococci, and2 Institut fu¨r Organische Chemie und Biochemie
Technische Universita¨t Mu¨nchen penicillin-resistant streptococci [3–6] and are therefore
interesting candidates for the generation of new thera-Lichtenbergstraße 4
85747 Garching peutics. Evernimicin (Ziracin), which is structurally very
similar to avilamycin, already passed through clinicalGermany
3 Institut fu¨r Mikrobiologie und Hygiene studies phase II and phase III. Due to a mismatch of
activity to side effects and due to impurities in the drug,Albert-Ludwigs-Universita¨t Freiburg
Hermann-Herder-Strasse 11 its further development as a drug was stopped by Scher-
ing-Plough in May 2000 [7, 8]. Both avilamycin and ever-79104 Freiburg
Germany nimicin were shown to inhibit protein biosynthesis by
binding exclusively to the 50S ribosomal subunit of bac-
terial ribosomes [9, 10]. Recently we reported that meth-
ylation of G2535 and U2479 in domain V of the 23SSummary
rRNA confers resistance to avilamycin by preventing the
antibiotic from binding to the ribosome [11]. This wasThe oligosaccharide antibiotics avilamycin A and C are
produced by Streptomyces viridochromogenes Tu¨57. in accordance with results obtained by footprinting avi-
lamycin on Escherichia coli ribosomal subunits [12].Both consist of a heptasaccharide chain, which is
attached to a polyketide-derived dichloroisoeverninic Based on these data, it is suggested that avilamycin
interacts with the ribosomal A-site and interferes withacid moiety. They show excellent antibiotic activity
against Gram-positive bacteria. Both molecules are initiation factor IF2 and tRNA binding. No crossresis-
tance to other antibiotics has been described. Avila-modified by O-methylation at different positions, which
contributes to poor water solubility and difficulties in mycin and other orthosomycins show only poor solubil-
ity in water, which makes their therapeutical use difficult.galenical drug development. In order to generate novel
avilamycin derivatives with improved polarity and im- Therefore, it is of interest to investigate whether new,
structurally modified avilamycin derivatives may be ableproved pharmacokinetic properties, we generated a
series of mutants with one, two, or three mutated to overcome the limitations of the known compounds.
Avilamycin A contains at least five methyl groups, pre-methyltransferase genes. Based on the structure of
the novel avilamycin derivatives, the exact function sumably transferred by methyltransferases, which con-
tribute to its lipophilic character. We have already func-of three methyltransferases, AviG2, AviG5, and AviG6,
involved in avilamycin biosynthesis could be assigned. tionally identified two of these methyltransferases,
AviG1, which is a C-methyltransferase and is involved
in evalose biosynthesis [13], and AviG4, which is anIntroduction
O-methyltransferase and is responsible for methylation
of the phenolic hydroxyl group in the dichloroisoever-Antibiotic resistance is increasing dramatically among
ninic acid moiety [14]. While an aviG1-defective mutantboth Gram-positive and Gram-negative bacteria [1]. The
did not produce any avilamycin derivatives, the aviG4continuous evolution of new resistance mechanisms re-
mutant (S. viridochromogenes GW4) produced novel de-sults in a permanent need for the development of novel
rivatives. The major compounds were named gaviba-drugs. Avilamycin, a natural product of Streptomyces
mycin A1 and A3. Sequence analysis of the avilamycinviridochromogenes Tu¨57 (S. viridochromogenes Tu¨57),
biosynthetic gene cluster [14] led to the identificationalong with curamycins, everninomycins, and flamba-
of three additional putative methyltransferase genes,mycins, belongs to the orthosomycin class of antibiotics
i.e., aviG2, aviG5, and aviG6 (Figure 2). In this study, we[2]. Structural features of the avilamycins are a terminal
report the functional identification of aviG2, aviG5, anddichloroisoeverninic acid moiety (residue A in Figure 1)
aviG6 by means of targeted gene inactivation, the gener-and a heptasaccharide side chain consisting of D-oli-
ation of double and triple mutants, and the productionvose (residues B and C), 2-deoxy-D-evalose (residue
of new antibiotically active secondary metabolites. This
work sets the stage for the genetic engineering of further*Correspondence: andreas.bechthold@pharmazie.uni-freiburg.de
chemically inaccessible, modified avilamycin deriva-(A.B.); glaser@ch.tum.de (S.J.G.)
4 These authors contributed equally to this work. tives and the generation of novel potent antibiotics.
Chemistry & Biology
1404
Figure 1. Structure of Avilamycin A
Methyl groups, investigated during these
studies, are shown in bold and are denoted
as “groups” 1–4.
Results and Discussion after transformation of S. viridochromogenes GW4-
GW2, S. viridochromogenes GW4-GW5, and S. virido-
chromogenes GW4-GW6 with pSET-G4erm containingSequence Analysis of aviG2, aviG5, and aviG6
aviG4 behind the ermE* promoter [14]. To determineBesides aviG1 and aviG4, three further putative methyl-
clearly that the mutation event affected only the desiredtransferase genes, aviG2, aviG5, and aviG6, could be
genes and not other genes, aviG2, aviG5, and aviG6detected in the avilamycin biosynthetic gene cluster [13,
were ligated behind the ermE* promoter, cloned into14]. The predicted gene product of aviG2 comprises 241
the integration plasmid pSET152, and introduced byamino acids and shows only low sequence similarity to
protoplast transformation into the corresponding mu-putative methyltransferases in the database (e.g., 31%
tants. Gavibamycin A1 and A3 (derivatives of mutantidentity to a putative methyltransferase of Deinococcus
S. viridochromogenes GW4) production was restoredradiodurans) [15]. The protein coded by aviG5 consists
in each case. The amount of gavibamycin A1 and A3of 239 amino acids and is similar to a methyltransferase
produced by the complemented mutants was similar toin Bacillus cereus ATCC 14579 (29% identical amino
the amount produced by S. viridochromogenes GW4.acids). Database comparison with the deduced product
of aviG6 (240 amino acids) revealed similarity to a puta-
Isolation and Identification of Novel Avilamycintive methyltransferase from S. avermitilis [16] (33% iden-
Derivatives Produced by the Defective Mutantstical amino acids). Characteristic sequence regions,
S. viridochromogenes Tu¨57, the aviG4 mutant S. viri-which are usually found in S-adenosylmethionine-depen-
dochromogenes GW4, the double gene replacementdent methyltransferases [17], could be detected. Con-
mutants S. viridochromogenes GW4-GW2, S. virido-served motif I (V/I/L)(L/V)(D/E)(V/I)G(G/C)G(T/P)G, motif
chromogenes GW4-GW5, and S. viridochromogenesII (P/G)(Q/T)(F/Y/A)DA(I/V/Y)(F/I)(C/V/L), and motif III
GW4-GW6, the triple gene replacement mutant S. viri-LL(R/K)PGG(R/I/L)(L/I)(L/F/I/V)(I/L) are present in AviG2,
dochromogenes GW4-GW2-GW5, as well as S. virido-motif I and motif II are present in AviG5, and motif I is
chromogenes GW2, S. viridochromogenes GW5, andpresent in AviG6.
S. viridochromogenes GW6 were grown under the con-
ditions described in the Experimental Procedures. Ex-
Generation of S. viridochromogenes GW4-GW2, tracts from culture supernatants were analyzed by TLC,
S. viridochromogenes GW4-GW5, HPLC-UV, and HPLC/ESI-MS. Avilamycin A ([MNa]:
S. viridochromogenes GW4-GW6, 1425) and avilamycin C ([MNa]: 1427) were detected
S. viridochromogenes GW4-GW2-GW5, in extracts of S. viridochromogenes Tu¨57 as sodium
S. viridochromogenes GW2, S. viridochromogenes adduct ions ([M23]). The observed distributions of
GW5, and S. viridochromogenes GW6 the isotopic patterns of the pseudomolecular ions were
and Complementation Experiments in accordance with calculated values. With the assign-
For the generation of methyltransferase mutants (double ment of molecular masses, avilamycin A was produced
gene replacement mutants), gene inactivation experi- as main compound. The molecular masses of the pseu-
ments were carried out. Plasmids pMIKG2, pMIKG5, domolecular ions detected as the respective sodium
and pSP1-aviG6m were constructed as described in the adduct ions of two major compounds produced
Experimental Procedures, allowing the replacement of by S. viridochromogenes GW4-GW2, S. viridochromo-
the wild-type gene by a mutated allele in S. viridochro- genes GW4-GW5, and S. viridochromogenes GW4-GW6
mogenes GW4. For the generation of the triple mutant were [MNa]  1397 and [MNa]  1399, indicating
S. viridochromogenes GW4-GW2-GW5 defective in the loss of two methyl groups in comparison to the wild-
three methyltransferase genes, plasmid pMIKG5 was type avilamycin A and C. S. viridochromogenes GW4-
used as inactivation plasmid and S. viridochromogenes GW2-GW5 gave masses of [MNa]  1383 and
GW4-GW2 as host strain (Figure 3). The deletions within [MNa] 1385, which is in accordance with avilamycin
the methyltransferase genes were confirmed by PCR. A and C derivatives missing three methyl groups.
PCR fragments obtained from the double crossover mu- S. viridochromogenes GW2, S. viridochromogenes GW4,
tants using primers G2R and G2F, G5R and G5F, and S. viridochromogenes GW5, and S. viridochromogenes
G6R and G6F, respectively, could not be digested by GW6 gave masses of [MNa]  1411 and [MNa] 
SphI, XhoI, and AatII, respectively, whereas the PCR 1413, which are in accordance with avilamycin A and C
fragments obtained from S. viridochromogenes GW4 missing one methyl group.
could be digested by the enzymes. In all cases, Southern
hybridization confirmed these results (data not shown). NMR Analysis of Avilamycin A and Derivatives
S. viridochromogenes GW2, S. viridochromogenes In order to determine which methyl groups of avilamycin
A and avilamycin C, respectively, were affected in ourGW5, and S. viridochromogenes GW6 were obtained
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Figure 2. Genetic Organization of the Avila-
mycin Biosynthetic Gene Cluster
Genes belonging to the cluster are indicated
as dark arrows. Methyltransferase genes are
shown as black arrows.
mutants, it was necessary to complete the partial previ- The HMQC spectra of the derivatives (only avilamycin
A analogs) produced by the mutants are shown in Fig-ous assignment [18, 19] of the 1H and 13C resonances
of avilamycin A (see Supplemental Data). Samples were ures 4B–4E. As expected, in the spectrum of samples
obtained from S. viridochromogenes GW4, the signal ofavailable both partially 13C-labeled and unlabeled. The
partially labeled products were prepared by feeding the group 1 is missing (Figure 4B). In samples obtained
from S. viridochromogenes GW4-GW2, this group is alsobacteria with 13C-labeled L-methionine. This resulted in
13C-labeling of the carbons of the methoxy group in the absent, as well as group 4 (see Figure 4C). Samples
obtained from S. viridochromogenes GW4-GW5 lackdichloroisoeverninic acid moiety (group 1), of the me-
thoxy group at position C4 of the fucose moiety (group group 1 and group 2 (Figure 4D). Due to the partial
overlap of the signal of groups 2 and 3 in Figure 4A, an2), of the methoxy group at position C2 of the mannose
moiety (group 3), of the methoxy group at position C6 unequivocal identification of the methoxy signal at 3.43
ppm was not possible based on chemical shift informa-of the mannose moiety (group 4), as well as the methyl-
group at position C3 of the evalose moiety and the meth- tion only. However, the chemical shift of the signal sug-
gests the presence of group 3. This assumption is furtherylene group of the eurekanate (Figure 1). The NMR ana-
lysis was complicated due to severe overlapping of supported by the fact that the chemical shifts of all spins
in the vicinity of group 2 in the fucose moiety in samplessignals. For instance seven of the ten hydrogen signals
of the mannose moiety have resonances within 0.3 of S. viridochromogenes GW4-GW5 are significantly
changed compared to the wild-type avilamycin, indicat-ppm. Furthermore, the labeled samples were available
only in relatively low quantities (concentration of S. viri- ing the absence of group 2. The signals of the mannose
moiety and of the C1 position of the fucose moiety weredochromogenes GW4-GW5 sample about 3 mmol/liter;
concentration of wild-type avilamycin A sample about unchanged. The presence of group 3 is affirmed by the
observation of key NOEs, indicating the close spatial45 mmol/liter).
The assignment of the four methyl groups of interest proximity of the methoxy group to protons in the lyxose-
and mannose moieties (Figure 5). For the S. viridochro-of the wild-type avilamycin A is shown in the HMQC
spectrum in Figure 4A. The assignments of groups 1 mogenes GW4-GW6 sample (Figure 4E), an identifica-
tion of the methoxy signal at 3.43 ppm was also notand 4 were straightforward and are consistent with the
literature data. The partially overlapping resonances of possible based on chemical shift information alone.
However, the HMBC spectrum showed clear cross-groups 2 and 3 could be unequivocally assigned based
on HMBC data. peaks, which allowed the unequivocal assignment of
Figure 3. Methyltransferase Mutants Gener-
ated in This Study
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Figure 4. Sections of the HMQC Spectra
Sections of the HMQC spectra of (A) wild-
type avilamycin A and of derivatives pro-
duced by the mutants S. viridochromogenes
(B) GW4, (C) GW4-GW2, (D) GW4-GW5, and
(E) GW4-GW6. The contour level was chosen
such that only the methoxy group signals are
visible. The boxes indicate the reference po-
sitions of methoxy groups 1–4 of Figure 4A.
the remaining signal to group 2, indicating that group 3 position 4 of the D-fucose moiety, and AviG6 for methyl-
ation of the hydroxyl group at position 2 of the D-man-is missing in extracts of this mutant. From these results,
it is deduced that AviG2 is responsible for methylation nose moiety. In consideration of the results of HPLC/
ESI-MS analysis, the structure of the avilamycin C ana-of the hydroxyl group at position 6 of the D-mannose
moiety, AviG5 for methylation of the hydroxyl group at logs could also be assigned. New derivatives were
named gavibamycins (Figure 6).
Isolation of Gavibamycin Derivatives
for Biological Testing
For biological studies, avilamycin A and the correspond-
ing gavibamycin derivatives were isolated from S. viri-
dochromogenes Tu¨57 and from each mutant respec-
tively after cultivation of 6–12 liters medium. A total of
1–2 mg/l avilamycin A could be isolated from extracts
of S. viridochromogenes Tu¨57. A total of 1–2 mg/l gavi-
bamycin derivatives corresponding to avilamycin A
could be isolated from S. viridochromogenes GW4,
S. viridochromogenes GW2, and S. viridochromogenes
GW6. S. viridochromogenes GW5, S. viridochromo-
genes GW4-GW2, S. viridochromogenes GW4-GW5,
and S. viridochromogenes GW4-GW6 gave around 0.1–
0.3 mg/l. The decrease in productivity was not due to
a decreased efflux as determined by cell lysis, but was
Figure 5. 1D Slice of a 13C-Filtered NOESY Spectrum of the Sample mainly due to the instability of the gavibamycin deriva-
Derived from S. viridochromogenes GW4-GW5 Showing the NOE
tives. Degradation to nonactive compound was ob-Contacts of the Methoxy Group at 3.43 ppm
served in each case (data not shown).The purity of each
The NOEs show the spatial proximity of protons in the lyxose and
sample was 90% as determined by HPLC-UV- andmannose moieties to the methoxy group supporting the assignment
HPLC/ESI-MS analysis. S. viridochromogenes GW4-of this signal to group 3. The asterisk marks the NOE to the proton
of the OH group at C38 in ring F. GW2-GW5 produced less than 0.1 mg/l. As the gaviba-
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Figure 6. Structure of Compounds Gener-
ated during This Study
mycin derivatives of this mutant (gavibamycin H1 and GW2, GW4-GW5, GW4-GW6, GW4, GW2, GW5, GW6,
and wild-type avilamycin A were tested against a panelH3) were very unstable, we could not isolate enough
material for biological studies. of pathogenic Gram-positive organisms, including two
vancomycin-resistant strains, using the microdilution
assay. The antibacterial activity of each derivativePhysicochemical and Biological Properties
of Gavibamycin Derivatives against the clinical isolates is presented in Table 2. All
isolates were susceptible to avilamycin A (MIC range,The logP coefficient describes the distribution of a com-
pound between n-octanol and water and is used to com- 0.25 to 4 g/ml). Activity of avilamycin A was good
against Streptococcus and Enterococcus strains andpare hydrophilic properties of pharmaceutical drugs.
The logP coefficient was determined for each derivative. good to moderate against Staphylococcus strains. All
gavibamycin derivatives were less active against En-As shown in Table 1, the loss of one or two methyl
groups influences the polarity of the novel gavibamycin terococcus strains, slightly less active against Staphylo-
coccus strains and Streptococcus pyogenes, and asderivatives and increases the water solubility of unmeth-
ylated derivatives in general. The loss of the methyl active as avilamycin A against Streptococcus pneu-
moniae.group of the 4-O-methyl-D-fucose moiety has the
strongest influence on the polarity. The logP value for The removal of the methyl group of orsellinic acid
drastically affected the activity against Streptococcusgavibamycin E1, the major product of S. viridochromo-
genes GW4-GW5, is 1 unit lower than the coefficient pyogenes E12449/98. In contrast, activity against En-
terococcus faecalis ATCC19212, Enterococcus faecalisfound for avilamycin A, indicating a 10-fold higher water
solubility (Figure 6). H10513/99, and Enterococcus faecium Vanco-H8914/
00 was influenced by the polarity of the compounds andExtracts of our mutants were pretested against Bacil-
lus subtilis using the agar diffusion test. Antibiotic activ- was not dependent on a special methyl group of the
molecule.ity could be detected in each case. Furthermore, all
gavibamycin derivatives of S. viridochromogenes GW4- These results, biological as well as physicochemical,
Table 1. The Logarithm of the Partition Coefficient between N-Octanol and Water of Compounds Generated during This Study
Avilamycin Gavibamycin
A A1 L1 J1 I1 K1 C1 E1
Strain Wild-Type GW4 GW6 GW2 GW4-GW6 GW5 GW4-GW2 GW4-GW5
logP 4.24 4.00 3.94 3.70 3.67 3.49 3.46 3.22
The logarithm of the partition coefficient between n-octanol and water (logP) was determined by HPLC [41].
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Table 2. Minimum Inhibitory Concentration of Avilamycin Derivatives Determined by Microdilution According to NCCLS Guidelines
Gavi. Gavi. Gavi. Gavi. Gavi. Gavi. Gavi.
Avi. A Vancomycin J1 A1 K1 L1 C1 E1 I1
Staphylococcus aureus ATCC 2 1 4 8 4 2 4 8 8
25923
MRSA RV 5/98 4 0.5 2 4 4 2 4 8 8
Staphylococcus epidermidis 2 1 4 4 4 2 4 8 8
DSM 1798
Streptococcus pyogenes 0.25 0.25 0.25 2 0.5 0.25 1 2 1
E12449/98
Streptococcus pneumoniae 0.25 0.25 0.25 0.5 0.25 0.25 0.5 0.5 0.5
E2919/94
Enterococcus faecalis 0.5 0.25 4 2 8 4 16 16 16
ATCC 19212
Enterococcus faecalis H10513/99 0.5 128 4 1 4 4 8 8 8
Enterococcus faecium 2 128 32 8 32 16 64 32 32
Vanco-H8914/00
Avi., avilamycin; gavi., gavibamycin.
NL19 medium containing 2% D-mannitol, 2% soy flour, and 20indicate that our strategy of gene inactivation and gener-
mM L-valine (adjusted to pH 7.5). For improved production, SGation of double and triple mutants to get novel, antibioti-
medium containing 2% D-glucose, 1% soy peptone, 0.1% CaCO3,cally active avilamycin derivatives in a nonchemical syn-
20 mM L-Valin, and 1 ml of 0.1% CoCL2 solution was used. Boththetic way is a promising method and a step toward the media were adjusted to pH 7.2. DNA manipulation was carried out
development of new antibiotics in order to overcome using Escherichia coli (E. coli) XL-1 Blue MRF (Stratagene) as the
host strain. Before transforming S. viridochromogenes strains, plas-problems in the treatment of infections caused by multi-
mids were propagated in E. coli ET 12567 (dam, dcm, hsdS, CmR)resistant pathogens.
[21] to obtain unmethylated DNA. E. coli strains were grown onThe reduced activity of the novel derivatives might be
Luria-Bertani (LB) agar or liquid medium containing the appropriateexplained by a decreased permeability of the gaviba-
antibiotic. pBluescript SK (pBSK) and pBC-SKwere from Stra-
mycin derivatives through the cell membrane. The use tagene. Plasmids pUC19 and pSP1 [22], conferring erythromycin
of gavibamycin derivatives together with-lactame anti- resistance, were a kind gift of Dr. S. Pelzer, Tu¨bingen, and pSET152
[23], conferring apramycin resistance, was obtained from Eli Lilly &biotics could be an interesting strategy to help to over-
Co. (Indianapolis, IN). The construction of pMun2 [24] and pSET-come this effect. Further preclinical experiments have
1cerm [25] has been described.to be performed to evaluate the use of gavibamycin
derivatives as new agents for the treatment of serious
General Genetic Manipulation, PCR, and Sequence Analysisinfections caused by pathogen microorganisms.
Standard molecular biology procedures were performed as de-
scribed [26]. Isolation of E. coli plasmid DNA, DNA restriction, DNA
modification, and Southern hybridization were performed followingSignificance
the protocols of the manufacturers of kits, enzymes, and reagents
(Amersham Biosciences, Roche Diagnostics, Promega, Stratagene).The avilamycin biosynthetic genes aviG2, aviG5, and
Streptomyces protoplast formation, transformation, and protoplastaviG6 encode methyltransferases methylating differ-
regeneration were performed as described [27]. PCR was carried out
ent sites of the avilamycin molecule. Our data indicate using a Perkin Elmer GeneAmp 2400 thermal cycler. Oligonucleotide
that AviG2, AviG5, and AviG6 act at a late step during primers used were G2F (5-CCGCCAATTGTGGCCCACGA-3), G2R
(5-CTCGGTCTAGAGCCGTCCCA-3), G5F (5-CCTCAATTGGCCCavilamycin biosynthesis. Partially nonmethylated sub-
CGCCGAA-3), G5R (5-GCGCAGATCTTCGTCGGTGA-3), G6F (5-strates are accepted by these methyltransferases,
GGACGAATTCCTGGCCGACG-3), and G6R (5-AGCGTCTAGATGdemonstrating that a strict order for methylation is not
GTGTCGTGCATG-3) (restriction sites are underlined). Reactionrequired. The majority of clinically useful antibiotics
conditions involved 35 cycles of denaturating at 95	C for 1:30 min,
interact with only a few sites in the large ribosomal annealing for 1:00 min and extending at 72	C for 1:45 min. Annealing
subunit, confined primarily to the peptidyl transferase temperatures used were 56	C in the case of aviG2, 62	C in the case
of aviG5, and 66	C in the case of aviG6. Computer-aided sequencecenter and entrance to the nascent peptide exit tunnel.
analysis was done with the DNASIS software package (version 2.1,In contrast, orthosomycins like avilamycin and ever-
1995; Hitachi Software Engineering). Database searches were per-nimicin bind to a novel site in the ribosome, which is
formed with the BLAST 2.0 program [28] on the server of the Nationalnot used by any other therapeutically important drug.
Center for Biotechnology Information, Bethesda, MD.
Clearly, this study has provided significant insights
into the biosynthesis of avilamycin A and allowed the Construction of Gene Inactivation Plasmids
generation of novel, potentially valuable antibiotics. aviG2
The aviG2 gene, located on a 1.8 kb EcoRI/BamHI fragment, was
ligated into pBC SK. After SphI restriction, treatment with theExperimental Procedures
Klenow fragment of E. coli DNA polymerase I, and religation, the
intended alteration was confirmed by DNA sequencing. The mutatedBacterial Strains, Plasmids, and Culture Conditions
S. viridochromogenes Tu¨57 [20] and all mutants were grown on 1% 1.8 kb fragment was cloned in pSP1 to generate plasmid pMIKG2.
aviG5malt extract, 0.4% yeast extract, 0.4% glucose, and 1 mM CaCl2
(pH adjusted to 7.2 [HA medium] at 37	C). For avilamycin production, A 3.2 kb EcoRI/BamHI fragment containing aviG5 was ligated into
pBC SK to create plasmid pE624. After restriction with EcoRI andS. viridochromogenes Tu¨57 and all mutants were grown at 28	C in
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XbaI, the insert was transferred to plasmid pSP1 to generate pSP1- with 0.5% acetic acid as solvents (nonlinear gradient from 20% to
100% acetonitrile in 20 min, at a flow rate of 1.2 ml/min). The detec-E624/7. A unique XhoI restriction site was then used for modification
in a similar way as described for aviG2. DNA sequencing showed tion wavelength was 220 nm. Detection and spectral characteriza-
tion of peaks were accomplished with a photodiode array detectorthat treatment with T4 DNA polymerase led to a 50 bp deletion in
aviG5. The resulting plasmid pMIKG5 was used for further experi- and Millennium software (Waters Associates; Eschborn).
HPLC/ESI-MS Analysisments.
aviG6 HPLC/ESI-MS was performed on an Agilent 1100 Series System
with an electrospray chamber and a quadrupole detector. HPLCAn EcoRI and an XbaI restriction site were introduced upstream
and downstream to aviG6 using primers G6F and G6R. After restric- analysis was carried out on a Zorbax SB-C18 5 m, 4.6 
 150 mm
column with a Zorbax SB-C18 5 m, 4.6 
 12.5 mm precolumntion with EcoRI and XbaI, a 1 kb fragment containing aviG6 was
ligated into plasmid pBC SK to generate plasmid pBC-aviG6. A (Agilent). A nonlinear gradient from 20% to 70% acetonitrile in 0.5%
acetic acid over 22 min at a flow rate of 0.5 ml/min was used. Theunique AatII restriction site was altered by AatII restriction and sub-
sequent treatment as described for aviG2. Sequencing revealed column temperature was 23	C, and the UV detection wavelengths
were 254 and 300 nm. The MSD chamber settings were as following:the correct alteration. The 1 kb fragment was cloned into pSP1 to
generate plasmid pSP1-aviG6m. drying gas flow 12 liter/min, nebulize pressure 50 psig, drying gas
temperature 300	C. The samples were analyzed in positive and neg-Plasmids pMIKG2, pMIKG5, and pSP1-aviG6m were used to gen-
erate methyltransferase mutants as described [14]. As host, we used ative scan mode with a mass range of 700–1500 Da.
NMR Analysisthe aviG4 gene replacement mutant S. viridochromogenes GW4 [14].
NMR spectra were recorded in DMSO-d6 at 295 K on Bruker DMX
600 and 750 MHz spectrometers. The following experiments wereConstruction of Complementation Plasmids
initially acquired at 600 MHz. 1H-1D, 13C-1D, COSY [29], TOCSY [30,For the generation of plasmids used to complement the methyltrans-
31], NOESY [32], HMQC [33] (HSQC [34] for S. viridochromogenesferase mutants, aviG2, aviG5, and aviG6 were amplified by PCR.
GW4-GW6), and HMBC [35]. To solve remaining problems, addi-Suitable restriction sites (aviG2, MunI and XbaI; aviG5, MunI and
tional spectra were measured for the wild-type sample and theBglII; aviG6, EcoRI and XbaI) were introduced upstream and down-
samples of S. viridochromogenes GW4-GW5 and S. viridochromo-stream of each gene using oligonucleotide primers G2F and G2R,
genes GW4-GW6 at a 750 MHz spectrometer: HMQC-COSY [36],G5F and G5R, and G6F and G6R, respectively. The PCR product of
HSQC-TOCSY [37], and 13C-filtered-NOESY [38] (mixing time:aviG5 was restricted with MunI and BglII and ligated into plasmid
200 ms). Both spectrometers are part of the Bavarian NMR CenterpMun2 to create plasmid pMun2-aviG5. Plasmid pSET-1cerm was
in Garching. Spectra were assigned using the program SPARKYdigested with MunI and XbaI to remove urdGT1c, and the fragment
3 [39].containing aviG5 was cloned behind the ermE* promoter in place
of urdGT1c after restriction digestion of pMun2-aviG5 using MunI
Isolation of Novel Gavibamycin Derivativesand XbaI. The resulting complementation plasmid was named pSET-
for the Determination of PhysicochemicalG5. The PCR product of aviG2 was restricted with MunI and XbaI
and Biological Propertiesand ligated behind aviG5 into the EcoRI and XbaI sites of plasmid
Strains were grown in SG medium for 3–4 days. Cultures were fil-pMun2-aviG5 to form plasmid pMun2-aviG5G2. To generate the
tered, and the filtrate was extracted twice by ethyl acetate. Thecomplementation plasmid pSET-G5G2 the MunI/XbaI fragment of
mycelium was broken with acetone and filtered again. After evapora-pMun2-aviG5G2 containing aviG5 and aviG2 was cloned behind the
tion of acetone, it was also extracted by ethyl acetate and evapo-ermE* promoter in place of urdGT1c in plasmid pSET-1cerm. To
rated to dryness. Crude extracts were combined and applied to agenerate the complementation plasmid pSET-G2, the PCR product
solid-phase extraction cartridge (SepPak C18, Waters Associates).obtained was digested by MunI and XbaI and was ligated behind
The cartridge was eluted with 50% and 80% methanol. The 80%the ermE* promoter in place of urdGT1c in plasmid pSET-1cerm.
fraction contained about 90% of the avilamycin derivatives. TheFor construction of the integration plasmid pSET-G6, the PCR prod-
evaporated and lyophilisized fractions were redissolved in acetonitriluct of aviG6 was restricted using EcoRI and XbaI and cloned into
and water. Further isolation was performed on an Agilent 1100 sys-the MunI and XbaI sites of pSET-1cerm after removal of urdGT1c.
tem using a semipreparative column (Zorbax SB-C18, 9.4 m 

150 mm; 5 m). For elution, the following gradient profile was used:Feeding of S. viridochromogenes Tu¨57 and All
solvent A: 5 mM ammoniumacetate in H2O; solvent B: acetonitrile,Methyltransferase-Defective Mutants
nonlinear gradient, 30%–50% B within 20 min at a flow rate of 3.5with 13C-Labeled L-Methionine
ml/min. A mass-based fraction collector was used to isolate theThe strains were grown at 28	C in NL19 medium (5 
 100 ml) as
avilamycin derivatives. The final isolation step was performed usingdescribed above. After 24 hr and 36 hr, 10 mg 13C-labeled
a gelpermeation column (PLgel 5 m; 100 A˚; 300 
 7.5 m; MW L-methionine was added to the culture. After 72 hr of cultivation,
4000). As solvent, acetonitril at a flow rate of 1 ml/ml was used.secondary metabolites were isolated as described in the following
Again, a mass-based fraction collector was used to isolate the avila-section and analyzed by NMR.
mycin derivatives.
Analysis of New Derivatives of Avilamycin A and C
Biological and Physicochemical PropertiesTLC Analysis
The antimicrobial activity of the new derivatives was determined byS. viridochromogenes Tu¨57 and mutants S. viridochromogenes
the agar plate diffusion assay [40] using Bacillus subtilis as the testGW4, S. viridochromogenes GW4-GW2, S. viridochromogenes
strain. Susceptibility of Staphylococci, Streptococci, and Entero-GW4-GW5, S. viridochromogenes GW4-GW2-GW5, and S. virido-
cocci to different derivatives was determined by the microdilutionchromogenes GW4-GW6 were incubated for 3 days. Cultures were
test according to NCCLS guidelines. The logarithm of the partitionfiltered, and the filtrate was applied to a solid-phase extraction
coefficient between n-octanol and water was determined bycartridge (SepPak C18, Waters Associates). The cartridge was eluted
HPLC [41].using a gradient from 10% to 100% methanol in water. Avilamycin
derivatives containing fractions were extracted by ethyl acetate.
Supplemental DataAfter evaporation of the organic solvent, avilamycin derivatives were
Chemical shifts (1H) of nonexchanging protons of avilamycin Aredissolved in methanol and analyzed by TLC on silica gel plates
and (13C) are given as supplemental information at http://www.(silica gel 60 F254, Merck) with methylene chloride/methanol (9:1, v/v)
chembiol.com/cgi/content/full/11/10/1403/DC1.as solvent. Avilamycin derivatives could be detected after treatment
with anisaldehyde/H2SO4.
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